IBER.U (Ibere Pharmaceuticals) Common Stock : $138.84 Mil (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Common Stock?

Ibere Pharmaceuticals's quarterly common stock increased from Mar. 2022 ($138.02 Mil) to Jun. 2022 ($138.11 Mil) and increased from Jun. 2022 ($138.11 Mil) to Sep. 2022 ($138.84 Mil).

Ibere Pharmaceuticals's annual common stock stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($138.02 Mil).

Ibere Pharmaceuticals Common Stock Historical Data

The historical data trend for Ibere Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Common Stock Chart

Ibere Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Common Stock

138.02

Ibere Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Common Stock	Get a 7-Day Free Trial			138.00	138.02	138.02	138.11	138.84

Ibere Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Ibere Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103

Website

https://www.iberepharma.com

Ibere Pharmaceuticals is a blank check company.

Executives

Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie	director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes	director, 10 percent owner, officer: Chief Operating Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray	director, 10 percent owner, officer: Chief Financial Officer	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu	director	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc	10 percent owner	2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021